196 related articles for article (PubMed ID: 25203782)
21. Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
Liu Y; Salvador LA; Byeon S; Ying Y; Kwan JC; Law BK; Hong J; Luesch H
J Pharmacol Exp Ther; 2010 Nov; 335(2):351-61. PubMed ID: 20739454
[TBL] [Abstract][Full Text] [Related]
22. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor.
Ying Y; Taori K; Kim H; Hong J; Luesch H
J Am Chem Soc; 2008 Jul; 130(26):8455-9. PubMed ID: 18507379
[TBL] [Abstract][Full Text] [Related]
23. A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling.
Liu Y; Wang Z; Wang J; Lam W; Kwong S; Li F; Friedman SL; Zhou S; Ren Q; Xu Z; Wang X; Ji L; Tang S; Zhang H; Lui EL; Ye T
Liver Int; 2013 Apr; 33(4):504-15. PubMed ID: 23279742
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and activity of largazole analogues with linker and macrocycle modification.
Ying Y; Liu Y; Byeon SR; Kim H; Luesch H; Hong J
Org Lett; 2008 Sep; 10(18):4021-4. PubMed ID: 18707106
[TBL] [Abstract][Full Text] [Related]
25. Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor.
Bowers A; West N; Taunton J; Schreiber SL; Bradner JE; Williams RM
J Am Chem Soc; 2008 Aug; 130(33):11219-22. PubMed ID: 18642817
[TBL] [Abstract][Full Text] [Related]
26. A fluorine scan on the Zn
Zhang B; Liu J; Gao D; Yu X; Wang J; Lei X
Eur J Med Chem; 2019 Nov; 182():111672. PubMed ID: 31505452
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold.
Bowers AA; West N; Newkirk TL; Troutman-Youngman AE; Schreiber SL; Wiest O; Bradner JE; Williams RM
Org Lett; 2009 Mar; 11(6):1301-4. PubMed ID: 19239241
[TBL] [Abstract][Full Text] [Related]
28. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
29. Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells.
Zeng X; Yin B; Hu Z; Liao C; Liu J; Li S; Li Z; Nicklaus MC; Zhou G; Jiang S
Org Lett; 2010 Mar; 12(6):1368-71. PubMed ID: 20184338
[TBL] [Abstract][Full Text] [Related]
30. Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5''-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity.
Narita K; Kikuchi T; Watanabe K; Takizawa T; Oguchi T; Kudo K; Matsuhara K; Abe H; Yamori T; Yoshida M; Katoh T
Chemistry; 2009 Oct; 15(42):11174-86. PubMed ID: 19760730
[TBL] [Abstract][Full Text] [Related]
31. Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere.
Pilon JL; Clausen DJ; Hansen RJ; Lunghofer PJ; Charles B; Rose BJ; Thamm DH; Gustafson DL; Bradner JE; Williams RM
Cancer Chemother Pharmacol; 2015 Apr; 75(4):671-82. PubMed ID: 25616967
[TBL] [Abstract][Full Text] [Related]
32. Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers.
Sanchez GJ; Richmond PA; Bunker EN; Karman SS; Azofeifa J; Garnett AT; Xu Q; Wheeler GE; Toomey CM; Zhang Q; Dowell RD; Liu X
Nucleic Acids Res; 2018 Feb; 46(4):1756-1776. PubMed ID: 29240919
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of novel FK228 analogues as potential isoform selective HDAC inhibitors.
Narita K; Matsuhara K; Itoh J; Akiyama Y; Dan S; Yamori T; Ito A; Yoshida M; Katoh T
Eur J Med Chem; 2016 Oct; 121():592-609. PubMed ID: 27318982
[TBL] [Abstract][Full Text] [Related]
34. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
Thaler F; Mercurio C
ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Cheng C; Yun F; He J; Ullah S; Yuan Q
Eur J Med Chem; 2019 Jul; 173():185-202. PubMed ID: 31003060
[TBL] [Abstract][Full Text] [Related]
36. Largazole: from discovery to broad-spectrum therapy.
Hong J; Luesch H
Nat Prod Rep; 2012 Apr; 29(4):449-56. PubMed ID: 22334030
[TBL] [Abstract][Full Text] [Related]
37. A concise total synthesis of largazole, solution structure, and some preliminary structure activity relationships.
Nasveschuk CG; Ungermannova D; Liu X; Phillips AJ
Org Lett; 2008 Aug; 10(16):3595-8. PubMed ID: 18616341
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
[TBL] [Abstract][Full Text] [Related]
39. Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells.
Zhang K; Yao Y; Tu Z; Liao C; Wang Z; Qiu Y; Chen D; Hamilton DJ; Li Z; Jiang S
Future Med Chem; 2020 Feb; 12(4):311-323. PubMed ID: 31782319
[No Abstract] [Full Text] [Related]
40. Combinatorial strategies by marine cyanobacteria: symplostatin 4, an antimitotic natural dolastatin 10/15 hybrid that synergizes with the coproduced HDAC inhibitor largazole.
Taori K; Liu Y; Paul VJ; Luesch H
Chembiochem; 2009 Jul; 10(10):1634-9. PubMed ID: 19514039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
